

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zai Lab Limited
再鼎醫藥有限公司*

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9688)

VOTING RESULTS OF EXTRAORDINARY GENERAL MEETING

Zai Lab Limited (the “**Company**”) held its extraordinary general meeting of shareholders on March 28, 2022 (the “**EGM**”). Holders of a total of 82,378,112 ordinary shares of the Company, constituting more than one-tenth of all voting share capital of the Company in issue as of the record date of February 18, 2022, were present in person by virtual attendance or by proxy at the EGM.

The matter set forth below was voted on by the Company’s shareholders and approved at the EGM. Detailed descriptions of the proposal and the applicable voting procedures at the EGM are contained in the circular/definitive proxy statement for the EGM on February 28, 2022, and the supplemental announcement to the circular/definitive proxy statement on March 23, 2022. The resolution duly proposed in the notice of the EGM, as set forth below, was approved at the EGM.

Proposal:

- (1) AS AN ORDINARY RESOLUTION: to authorize and approve a share subdivision whereby, with effect from March 30, 2022, subject to and conditional upon the Listing Committee of The Stock Exchange of Hong Kong Limited granting the listing of, and permission to deal in, (i) the Subdivided Ordinary Shares (as defined below), (ii) any Subdivided Ordinary Shares which may be issued upon exercise of the outstanding share options granted by the Company or any Subdivided Ordinary Shares which may be issued upon vesting of the share awards under the equity incentive plan adopted by the shareholders of the Company on August 21, 2015 (as amended on February 3, 2016 and April 10, 2016) (the “**2015 Equity Plan**”) and under the equity incentive plan adopted by the shareholders of the Company on August 11, 2017 (the “**2017 Equity Plan**”), and (iii) any Subdivided Ordinary Shares which may be issued upon the exercise of share options or any Subdivided Ordinary Shares which may be issued upon vesting of the share awards to be granted from time to time under the 2015 Equity Plan and the 2017 Equity Plan, (a) each issued and unissued Ordinary Share with a par value of US\$0.00006 each

(the “**Ordinary Share(s)**”) in the capital of the Company will be subdivided into ten Ordinary Shares with a par value of US\$0.000006 each (the “**Subdivided Ordinary Shares**”), and (b) the authorized share capital of the Company will be amended as follows:

FROM: US\$30,000.00 divided into 500,000,000 shares with a par value of US\$0.000006 each;

TO: US\$30,000.00 divided into 5,000,000,000 shares with a par value of US\$0.000006 each (the “**Share Subdivision**”).

The final voting result for the resolution is as follows:

For	Against	Abstentions	Broker Non-votes
82,350,538	21,786	5,788	—

Accordingly, this Proposal was carried as an ordinary resolution.

By order of the Board
Zai Lab Limited
Samantha Du
Director, Chairperson and Chief Executive Officer

Hong Kong, March 29, 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. Samantha Du as a director, and Dr. Kai-Xian Chen, Dr. John Diekman, Ms. Nisa Leung, Mr. William Lis, Mr. Leon O. Moulder, Jr., Mr. Peter Wirth, Mr. Scott W. Morrison and Mr. Richard Gaynor as the independent directors.

* *For identification only*